Samsung Bioepis, a Korean-based biopharmaceutical company, announced on Nov. 20, 2017 that its biosimilar, Ontruzant, which references Roche s Herceptin (trastuzumab), has received European regulatory approval for the treatment of early breast cancer, metastatic breast cancer, and metastaticOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.